Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao, Joyce Cheng, Erik Bloomquist, et al.
The Lancet Oncology (2019) Vol. 21, Iss. 2, pp. 250-260
Closed Access | Times Cited: 242

Showing 1-25 of 242 citing articles:

Breast cancer
Sibylle Loibl, Philip Poortmans, Monica Morrow, et al.
The Lancet (2021) Vol. 397, Iss. 10286, pp. 1750-1769
Closed Access | Times Cited: 1134
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1475-1495
Open Access | Times Cited: 850
Targeting cell-cycle machinery in cancer
Jan M. Suski, Marcin Braun, Vladislav Strmiska, et al.
Cancer Cell (2021) Vol. 39, Iss. 6, pp. 759-778
Open Access | Times Cited: 379
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M. Spring, Seth A. Wander, Fabrice André, et al.
The Lancet (2020) Vol. 395, Iss. 10226, pp. 817-827
Closed Access | Times Cited: 372
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
C. Louwrens Braal, Elisabeth M. Jongbloed, Saskia M. Wilting, et al.
Drugs (2020) Vol. 81, Iss. 3, pp. 317-331
Open Access | Times Cited: 300
Breast cancer: an up‐to‐date review and future perspectives
Ruoxi Hong, Binghe Xu
Cancer Communications (2022) Vol. 42, Iss. 10, pp. 913-936
Open Access | Times Cited: 196
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Hope S. Rugo, Aditya Bardia, Frederik Marmé, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 29, pp. 3365-3376
Closed Access | Times Cited: 192
Novel approaches to target the microenvironment of bone metastasis
Lorenz C. Hofbauer, Aline Bözec, Martina Rauner, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 488-505
Closed Access | Times Cited: 140
The Role of Progesterone Receptors in Breast Cancer
Zhuo Li, Hongrui Wei, Siyan Li, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 305-314
Open Access | Times Cited: 132
Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update
Harold J. Burstein, Mark R. Somerfield, Debra L. Barton, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 35, pp. 3959-3977
Open Access | Times Cited: 125
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 89-105
Closed Access | Times Cited: 109
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
Karen Van Baelen, Tatjana Geukens, Marion Maetens, et al.
Annals of Oncology (2022) Vol. 33, Iss. 8, pp. 769-785
Open Access | Times Cited: 80
Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives
Jun Wang, San-Gang Wu
Breast Cancer Targets and Therapy (2023) Vol. Volume 15, pp. 721-730
Open Access | Times Cited: 76
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer
Jason Mouabbi, Amy Hassan, Bora Lim, et al.
Breast Cancer Research and Treatment (2022) Vol. 193, Iss. 2, pp. 253-264
Closed Access | Times Cited: 70
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Wei Wang, Wenqian Lei, Ziru Fang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 49
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 16, pp. 3549-3563
Open Access | Times Cited: 34
Multi-stage mechanisms of tumor metastasis and therapeutic strategies
Zaoqu Liu, Jingqi Chen, Yuqing Ren, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 21
A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors
Sungjoon Park, Erica Silva, Akshat Singhal, et al.
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 996-1009
Open Access | Times Cited: 17
Breast cancer: pathogenesis and treatments
Xin Xiong, Lewei Zheng, Yu‐Qiang Ding, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 14
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Michela Piezzo, Stefania Cocco, Roberta Caputo, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6479-6479
Open Access | Times Cited: 137
Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
Francesco Schettini, Fabiola Giudici, Mario Giuliano, et al.
JNCI Journal of the National Cancer Institute (2020) Vol. 112, Iss. 11, pp. 1089-1097
Open Access | Times Cited: 85
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Michela Piezzo, Paolo Chiodini, Maria Riemma, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6400-6400
Open Access | Times Cited: 85
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group
Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 28, pp. 3171-3181
Open Access | Times Cited: 85
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
Yiling Wang, Audrey Minden
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11046-11046
Open Access | Times Cited: 66
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role
Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 62
Page 1 - Next Page

Scroll to top